<table>
<thead>
<tr>
<th>Date</th>
<th>Time PDT</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>29-Oct</td>
<td>06:00 - 07:00 AM</td>
<td>Molecular Profiling and Biomarkers</td>
<td>Expanding the scope of RNA-Seq to archival FFPE samples</td>
<td>Kelli Bramlett, M.S. Research &amp; Development Scientist, Thermo Fisher Scientific</td>
</tr>
<tr>
<td>29-Oct</td>
<td>06:00 - 07:00 AM</td>
<td>Drug Discovery</td>
<td>Nanotechnologies for Precision Medicine</td>
<td>Srinivas (Sri) Sridhar, PhD Director, NSF IGERT Nanomedicine Science and Technology Program, Director, Electronic Materials Research Institute, Arts and Sciences Distinguished Professor of Physics, Lecturer on Radiation</td>
</tr>
<tr>
<td>29-Oct</td>
<td>07:30 - 08:30 AM</td>
<td>Clinical Proteomics</td>
<td>Antibody-based Proteomics: Fast-Tracking Molecular Diagnostics and Target Discovery in Oncology</td>
<td>Darran O’Connor, PhD Senior Lecturer, School of Biomolecular &amp; Biomedical Science, Co-Director, Cancer Biology &amp; Therapeutics Laboratory, University of Dublin</td>
</tr>
<tr>
<td>29-Oct</td>
<td>07:30 - 08:30 AM</td>
<td>Molecular Profiling and Biomarkers</td>
<td>Making Clinical NGS possible</td>
<td>Vikram Devgan, PhD, MBA Director, Head of Biological research content, Qiagen, Inc.</td>
</tr>
<tr>
<td>29-Oct</td>
<td>09:00 - 10:00 AM</td>
<td>Drug Discovery</td>
<td>Targeting the oncogene eIF4E in leukemia reveals a new form of drug resistance</td>
<td>Katherine LB Borden, PhD Principal Investigator, Structure and Function of the Cell Nucleus research unit, Full Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Institut</td>
</tr>
<tr>
<td>29-Oct</td>
<td>09:00 - 10:00 AM</td>
<td>Drug Discovery</td>
<td>miRNA Biomarker Discovery: Technologies, workflows, and data analysis solutions for discovering your unique signature</td>
<td>Jonathan Shaffer, MBA, PhD Associate Director, NGS Assay Technologies, Qiagen</td>
</tr>
<tr>
<td>29-Oct</td>
<td>09:00 - 10:00 AM</td>
<td>Cancer Epigenetics</td>
<td>Reading and disrupting the histone code with chemical agents: making new tools to understand epigenetic methylation pathways in stem-like cancers</td>
<td>Fraser Hof, PhD Associate Professor, University of Victoria</td>
</tr>
<tr>
<td>29-Oct</td>
<td>09:00 - 10:00 AM</td>
<td>Molecular Profiling and Biomarkers</td>
<td>What’s wrong with biomarker development for cancer</td>
<td>Anna Barker, PhD Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU)</td>
</tr>
<tr>
<td>29-Oct</td>
<td>10:30 - 11:30 AM</td>
<td>Keynote</td>
<td>Learning from the Pointillists - Using Big Data Approaches to Embrace the Complexity of Cancer</td>
<td>Kenneth Buetow, PhD, FACMI Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University</td>
</tr>
<tr>
<td>Date</td>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------</td>
<td>---------------</td>
<td>--------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 29-Oct     | 12:00 - 01:00 PM | Therapeutics; Cancer Therapies & New Techniques | A Next-Gen Sequencing Software Workflow for Cancer Gene Panel Analysis | Kerri Phillips  
Clinical Research Product Manager, DNASTAR |
| 29-Oct     | 12:00 - 01:00 PM | Molecular Profiling and Biomarkers | Improving the Robustness and Reproducibility of Quantitative Proteomics | Michael MacCoss, PhD  
Professor of Genome Sciences, University of Washington, School of Medicine |
| 29-Oct     | 12:00 - 01:00 PM | Cancer Metabolism | Obesity, weight loss, and the microenvironment in basal-like breast cancer | Liza Makowski, PhD  
Assistant Professor, Nutrition, UNC Gillings School of Global Public Health |
| 29-Oct     | 01:30 - 02:30 PM | Therapeutics; Cancer Therapies & New Techniques | Metabolic therapy for the adjuvant treatment of malignant brain tumors | Adrienne C. Scheck, PhD  
Associate Professor, Neuro-Oncology Research, Barrow Brain Tumor Research Center, Barrow Neurological Institute |
| 29-Oct     | 01:30 - 02:30 PM | Molecular Profiling and Biomarkers | PDX Tumor Models for Oncology Research and Preclinical Prediction | Walter Ausserer, PhD  
Business Unit Management, Senior Business Unit Manager, The Jackson Laboratory |
| 29-Oct     | 01:30 - 02:30 PM | Cancer Metabolism | Protein phosphatase 2A in cell survival upon metabolic stress | Mei Kong, PhD  
Assistant Professor, Cancer Biology, City of Hope National Medical Center |
| 29-Oct     | 03:00 - 04:00 PM | Molecular Profiling and Biomarkers | Drug-tailored, efficacy-predictive and prognostic biomarker approaches for proper patient selection | Peter Blume-Jensen, MD, PhD  
Chief Scientific Officer, XTuit Pharmaceuticals, Inc. |
| 29-Oct     | 03:00 - 04:00 PM | Molecular Profiling and Biomarkers | Molecular Prognosis in the Management of Early Stage Lung Cancer | Michael J Mann, MD  
Associate Professor of Surgery, Division of Adult Cardiothoracic Surgery, Chief of General Thoracic Surgery, University of California, San Francisco, VA Medical Center |
| 29-Oct     | 03:00 - 04:00 PM | Therapeutics; Cancer Therapies & New Techniques | Transforming the future of oncology with genomics | Jennifer Stone, PhD  
Senior Market Manager, Oncology, Illumina |
| 30-Oct     | 06:00 - 07:00 AM | Molecular Profiling and Biomarkers | A platform for combining the results of WES and RNA-seq analysis | Naomi Thomson  
Director, Clinical Analytics and Workflow Products, CLC Bio, a Qiagen company |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session / Topic</th>
<th>Speaker Details</th>
</tr>
</thead>
</table>
| 30-Oct | 06:00 - 07:00 AM | Cancer Epigenetics | Epigenetic Dysregulation in the Pathogenesis of Myeloproliferative Neoplasms  
Kristin Landis-Piwowar, PhD, MLS  
Assistant Professor, Biomedical Diagnostic & Therapeutic Sciences, Oakland University |
| 30-Oct | 07:30 - 08:30 AM | Keynote | Challenges in biomarker testing in non-small cell lung cancer research  
Nicola Normanno, MD  
Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy |
| 30-Oct | 08:30 - 10:00 AM | Keynote | A head-to-head comparison of whole blood derived samples (cfDNA vs CTC DNA) for cancer research using next-generation sequencing  
Paul W. Dempsey, PhD  
Chief Science Officer, Cynvenio |
| 30-Oct | 10:30 - 11:30 AM | Molecular Profiling and Biomarkers | Development of molecularly targeted imaging agents and identification of novel targets in cancer  
Kimberly Kelly, PhD  
Associate Professor of Biomedical Engineering, University of Virginia |
| 30-Oct | 10:30 - 11:30 AM | Drug Discovery | Genomics in the Clinic: Promises and Challenges  
John Carpten, PhD  
Deputy Director of Basic Science, Professor and Director, Integrated Cancer Genomics Division, TGen |
| 30-Oct | 10:30 - 11:30 AM | Therapeutics; Cancer Therapies & New Techniques | Therapeutic Drug Monitoring (TDM) in Cancer Chemotherapy: A Tool for Optimizing Drug Management  
William Clarke, PhD, MBA, DABCC  
Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine |
| 30-Oct | 12:00 - 01:00 PM | Therapeutics; Cancer Therapies & New Techniques | Breast-Predict: Leveraging the Power of Systems Medicine Towards Personalized Cancer Therapy  
William M. Gallagher, BSc PhD CBiol MSB  
Chief Scientific Officer at OncoMark, Professor of Cancer Biology, University of Dublin |
| 30-Oct | 12:00 - 01:00 PM | Cancer Metabolism | The metabolic microenvironment in tumors and its impact on T-cell mediated immunity  
Julian J. Lum, PhD  
Scientist BC Cancer Agency's Deeley Research Centre, Assistant Professor Department of Biochemistry and Microbiology, University of Victoria |
| 30-Oct | 12:00 - 01:00 PM | Therapeutics; Cancer Therapies & New Techniques | What is best practice for testing for unexpected pregnancy in pediatric and adult patients prior to cancer diagnostics, imaging and therapy?  
Sharon M. Geaghan, MD  
Chief, Pathology at Lucile Packard Children's Hospital at Stanford, Associate Professor in the Department of Pathology, Stanford University |
| 30-Oct | 01:30 - 02:30 PM | Cell Signaling | Dissecting cancer signaling pathways with chemical scalpels  
Nadya Tarasova, PhD  
Head, Synthetic Biologics Core, Cancer and Inflammation Program, Center for Cancer Research National Cancer Institute |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-Oct</td>
<td>01:30-02:30 PM</td>
<td>Molecular Profiling and Biomarkers</td>
<td>Structural Pathways of Cancer</td>
<td>Ruth Nussinov, PhD Head, Computational Structural Biology Group, Senior Investigator, Center for Cancer Research, National Cancer Institute</td>
</tr>
<tr>
<td>30-Oct</td>
<td>03:00-04:00 PM</td>
<td>Drug Discovery</td>
<td>Clinical Shotgun Proteomics in Cancer Biomarker and Drug Target Research/Discovery</td>
<td>Josip Blonder, MD Senior Scientist, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research (FNLCR)</td>
</tr>
<tr>
<td>30-Oct</td>
<td>03:00-04:00 PM</td>
<td>Cancer Metabolism</td>
<td>Probing cancer metabolism using isotope tracers to identify therapeutic targets</td>
<td>Christian Metallo, PhD Principal Investigator, Metallo Lab, Assistant Professor, Bioengineering, University of California, San Diego</td>
</tr>
</tbody>
</table>